Alves Arthur Daniel Rocha, Magaldi Mariana, de Menezes Ana Carolina Sathler, França Lopes Josiane Iole, da Costa Silva Carlos Alexandre, de Oliveira Jaqueline Mendes, Mattos Camila, Bastos Leonardo, Amorim Filho Luiz de Melo, Pinto Marcelo Alves, Amado Luciane Almeida
Laboratório de Desenvolvimento Tecnológico em Virologia, Instituto Oswaldo cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti, Rio de Janeiro, RJ, Brasil.
Virol J. 2025 Jan 20;22(1):15. doi: 10.1186/s12985-025-02627-8.
Nonenveloped viruses, such as hepatitis A virus (HAV) and parvovirus B19 (B19V), are not inactivated by detergents and solvents commonly used to manufacture plasma derivatives. Cases of transfusion-transmitted HAV and B19V have already been described in several countries. This study aimed to determine the incidence of HAV and B19V asymptomatic infections in blood donors from Rio de Janeiro and evaluate the residual risk of transmission to blood derivative recipients.
From 2018 to 2019, 1,204 plasma samples were tested by PCR and real-time PCR. HAV and B19V genotypes were determined through sequencing and phylogenetic analysis. The risk of transfusion transmission was determined using a Bayesian statistical approach.
HAV-RNA and B19V-DNA were detected in 1.66 (95% CI 0.26-5.48) and 3.32 (95% CI 1.00-7.81) per 1000 donors, respectively. For HAV, all positive samples were classified as subgenotype IB. For B19V, the sequenced samples belonged to genotype 1A. The estimated numbers of infectious blood bags with HAV and B19V were 587 (95% CI 92-1936) and 880 (95% CI 355-2759), respectively.
This study originally assessed the incidence of both Hepatitis A Virus (HAV) and B19 Virus (B19V) among Brazilian blood donors, as well as the potential risk of residual transmission of these infections through blood transfusions. Our findings can contribute to future cost-effective studies aimed at implementing screening methods for these viruses, which could enhance discussion on surveillance in blood banks and protective measures for blood recipients.
无包膜病毒,如甲型肝炎病毒(HAV)和细小病毒B19(B19V),不会被常用于制造血浆衍生物的洗涤剂和溶剂灭活。在几个国家已经报道了经输血传播HAV和B19V的病例。本研究旨在确定里约热内卢献血者中HAV和B19V无症状感染的发生率,并评估向血液衍生物接受者传播的残余风险。
2018年至2019年,通过PCR和实时PCR对1204份血浆样本进行检测。通过测序和系统发育分析确定HAV和B19V的基因型。使用贝叶斯统计方法确定输血传播风险。
每1000名献血者中分别检测到1.66(95%可信区间0.26 - 5.48)例HAV - RNA和3.32(95%可信区间1.00 - 7.81)例B19V - DNA。对于HAV,所有阳性样本均归类为亚基因型IB。对于B19V,测序样本属于1A基因型。估计带有HAV和B19V的感染性血袋数量分别为587(95%可信区间92 - 1936)和880(95%可信区间355 - 2759)。
本研究首次评估了巴西献血者中甲型肝炎病毒(HAV)和B19病毒(B19V)的发生率,以及这些感染通过输血残余传播的潜在风险。我们的研究结果有助于未来开展旨在实施这些病毒筛查方法的具有成本效益的研究,这可能会加强关于血库监测和血液接受者保护措施的讨论。